SCHEMBL8328268

SCHEMBL8328268

CCN(CC)CC=Cc1ccc(C2CCCCC2)c(Cl)c1

nearest known ligand 0.76

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.76
TMEM97 Q5BJF2 1/20 0.76
EBP Q15125 1/20 0.76
KCNH2 Q12809 3/20 0.42
KDM4E B2RXH2 1/20 0.37
CEL P19835 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
EPOR P19235 1/20 0.32
ALDH1A1 P00352 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31
PTAFR P25105 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29412726 1.00 SIGMAR1 (0.76) SIGMAR1TMEM97EBPKCNH2KDM4E
SCHEMBL11634254 1.00 SIGMAR1 (0.76) SIGMAR1TMEM97EBPKCNH2KDM4E
Hydrochloric Acid SCHEMBL30570019 0.99 SIGMAR1 (0.74) SIGMAR1TMEM97EBPKCNH2KDM4E
SCHEMBL11631505 0.87 SIGMAR1 (0.72) SIGMAR1TMEM97EBPKDM4ECEL
SCHEMBL11633441 0.87 SIGMAR1 (0.72) SIGMAR1TMEM97EBPKDM4ECEL
SCHEMBL6648743 0.86 SIGMAR1 (1.00) SIGMAR1TMEM97EBPKCNH2KDM4E
SCHEMBL6648742 0.86 SIGMAR1 (1.00) SIGMAR1TMEM97EBPKCNH2KDM4E
SCHEMBL6652640 0.86 SIGMAR1 (1.00) SIGMAR1TMEM97EBPKCNH2KDM4E
SCHEMBL29412724 0.86 SIGMAR1 (1.00) SIGMAR1TMEM97EBPKCNH2KDM4E
SCHEMBL29629099 0.86 SIGMAR1 (1.00) SIGMAR1TMEM97EBPKCNH2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0917464-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1999-05-26 EP claimed
WO-1998004251-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1998-02-05 WO claimed
US-4104383-A PSYCHOSTIMULANT, ANTISPASMODIC, HYPOTENSIVE, ANALGESIC C M INDUSTRIES (FR) 1978-08-01 US claimed
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2023-11-16 US disclosed
EP-4213822-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS Therapeutics (FR) 2023-07-26 EP disclosed
EP-0917464-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1999-05-26 EP disclosed
WO-1998004251-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1998-02-05 WO disclosed
US-4104383-A PSYCHOSTIMULANT, ANTISPASMODIC, HYPOTENSIVE, ANALGESIC C M INDUSTRIES (FR) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS ACE, HAVCR2, FURIN SIGMAR1 3429/4885TMEM97 3055/4885EBP 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.